anthracycline

(redirected from Anthracyclines)

anthracycline

 [an″thrah-si´klēn]
a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agentsdaunorubicin and doxorubicin. The use of these drugs is limited by a chronic, cumulative, dose-related toxicity resulting in irreversible congestive heart failure.
Anthracycline. For daunorubicin, R1 = -CH3; for doxorubicin, R1 = -CHOH.

an·thra·cyc·line

(an'thra-sīk'lin, -lēn),
Anticancer agent consisting of three moieties: a pigmented aglycone, an amino sugar, and a lateral chain. Examples include doxorubicin, daunorubicin, and daunomycin (pirubicin).

anthracycline

/an·thra·cy·cline/ (-si´klēn) a class of antineoplastic antibiotics produced by Streptomyces peucetius and S. coeruleorubidus, including daunomycin and doxorubicin.
Enlarge picture
Anthracycline. For daunorubicin, R1=sbondCH3; for doxorubicin, R1=sbondCHOH.

anthracycline

Oncology A chemotherapeutic used in leukemia to prevent cell division Adverse effects Dose-dependent stomatitis, N&V and BM suppression which 'maxes' at ± 10 days; alopecia is normal; extravasation at IV injection site causes severe, protracted ulcers and necrosis. See Chemotherapy, Daunorubicin, Doxorubicin, Idarubicin.

anthracycline

a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agents daunomycin and doxorubicin. See also anthracycline antibiotic.
References in periodicals archive ?
This reliable, clinically validated assay determines the PITX2 DNA methylation ratio to differentiate between patients who are more likely or less likely to show beneficial response to anthracyclines, said Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area, for QIAGEN.
Anthracyclines are used to treat many types of cancer and are among the most common cancer therapies.
Annamycin is a unique liposome formulated anthracycline (also referred to in literature as "L-Annamycin") that has been designed to produce little to no cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat current anthracyclines.
Modern cancer agents include traditional chemotherapies such as anthracyclines, as well as newer targeted therapies and biologics.
For example, anthracyclines, which are among the most commonly used chemotherapeutic agents for treating children with cancer, are extremely effective, but they are also increase the risk of damage to the heart.
While anthracyclines are the most well-known and extensively investigated drugs with severe cardiotoxic effects, other drugs such as cyclophosphamide, a component of CHOP therapy (i.
The most serious side effect of anthracyclines is cardiotoxicity.
The use of echocardiography at baseline and for re- evaluation examinations to monitor patients exposed to anthracyclines was given a class-I recommendation by a task force of the ACC and the AHA6.
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity.
Furthermore, topoisomerase enzymes also appear active targets of anthracyclines in causing tumoricidal effect (Topoisomerase 2[alpha])
Anthracyclines are well known examples of these drugs.
The data shows that anthracyclines aren't necessary to treat early-stage breast cancer effectively and that cardiac and other associated toxicities can and should be avoided.